Description
A potent and selective S1P1 antagonist (IC50s = 2.5 and 2.0 nM for hS1P1 Ca2+ mobilization and in a GTPγS assay); inactive at S1P2, S1P3, and S1P4 receptors (IC50s = >20, >10, and >10 µM, respectively in a Ca2+ mobilization assay); reduces EAE disease severity in mice up to 26 days; induces pulmonary damage in rats when administered chronically